Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
暂无分享,去创建一个
Michael Wang | Michael L. Wang | S. Lonial | A. Chanan-Khan | A. Belch | J. Zeldis | I. Borrello | D. Weber | Christine I. Chen | Edward A Stadtmauer | Robert D Knight | E. Stadtmauer | Donna M Weber | Christine Chen | Ruben Niesvizky | Andrew Belch | David Siegel | Ivan Borrello | S Vincent Rajkumar | Asher Alban Chanan-Khan | Sagar Lonial | Zhinuan Yu | John Patin | Marta Olesnyckyj | Jerome B Zeldis | S. Rajkumar | R. Knight | Zhinuan Yu | D. Siegel | R. Niesvizky | M. Olesnyckyj | J. Patin | Marta Olesnyckyj
[1] Richard LeBlanc,et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.
[2] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[3] Robert A Kyle,et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. , 2005, Blood.
[4] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[5] G Muller,et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.
[6] John Crowley,et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. , 2006, Blood.
[7] Robert A Kyle,et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Fonseca,et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group , 2007 .
[9] Diane Warren,et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.
[10] B. Barlogie,et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.
[11] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.
[12] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[13] D. Weber,et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.